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Heart failure (HF) is a major public health challenge, 
accounting for significant morbidity and premature 
mortality globally, including in sub-Saharan Africa 
(SSA).[1] Owing to high prevalence and poor clin-
ical outcomes, HF is associated with recurrent 
hospitalisation and substantial healthcare expenditure.[2] In contrast to 
Western countries, where HF is considered a disease of older persons, 
in SSA it affects younger individuals.[1-3] Acute decompensated HF is 
the most common primary diagnosis for patients admitted to hospital 
with heart disease in SSA, and it is encountered at all levels of care.[1,3,4] 
The goals of the clinical approach to HF include: (i) correctly diag-
nosing the clinical syndrome of HF; (ii) identifying the underlying 
cause; and (iii) implementing an effective management strategy for 
symptom control, prolonging survival and reversing factors that 
predispose to precipitation of HF exacerbations. 
Definitions
HF is a clinical syndrome of effort intolerance characterised by 
breathlessness and fatigue, due to structural and functional abnormal-
ities of the myocardium, resulting in salt and water reten tion that is 
associated with neurohormonal adaptations, mainly in the renin-
angiotension-aldosterone system (RAAS). 
Ejection fraction is the stroke volume (end-diastolic volume minus 
the end-systolic volume) divided by the end-diastolic volume. Systolic 
dysfunction is reduced contraction and emptying of the left ventricle, 
and diastolic dysfunction is impaired relaxation of the left ventricular 
myocardium resulting in impaired filling of the left ventricle.
Epidemiology of HF in SSA
Although there have been no population-based epidemiological 
studies of HF in Africa, there have been a number of hospital-based 
studies that give important insights into the incidence and prevalence 
of HF in SSA. In contrast to other parts of the world, non-ischaemic 
aetiologies are predominant, with hypertension, rheumatic heart 
disease (RHD) and cardiomyopathy accounting for two-thirds of 
cases of HF in hospitalised patients in the region.[1,5] 
Classification of HF
Patients with HF can be divided into two categories: HF with 
reduced ejection fraction (HF-REF), and HF with preserved ejection 
fraction (HF-PEF) (Fig. 1). Although there is poor correlation 
between symptom severity and left ventricular ejection fraction 
(LVEF), the LVEF carries independent prognostic significance and 
is considered abnormal when <50%.[2] The diagnosis of HF-PEF is 
more difficult, and although LVEF is normal or only mildly reduced 
in this condition, relevant structural heart disease and/or diastolic 
dysfunction should be present to make this diagnosis. Importantly, 
HF-PEF is a diagnosis of exclusion where other non-cardiac causes 
for patients’ symptoms must be considered and discounted.[2] Patients 
with HF-PEF are older, more often female and obese, and more likely 
to have hypertension and atrial fibrillation, compared to those with 
HF-REF, and their prognosis appears to be better overall.[6]
Aetiology of HF in SSA
HF is a final common pathway for a number of conditions affecting 
the heart, and it is useful to classify the aetiology according to the 
following diseases: (i) hypertension; (ii) primary myocardial disease 
that includes cardiomyopathies and myocarditis; (iii) valvular heart 
disease; (iv) ischaemic heart disease; (v) congenital heart disease; 
(vi) pericardial disease; and (vii) pulmonary hypertension (PH) (Table 1). 
It is important to consider alternative causes for fluid retention (e.g. renal 
or liver disease) and pulmonary oedema (e.g. neurogenic) in the 
context of a structurally normal heart. 
Pathophysiology
Damage to cardiac myocytes and the extracellular matrix after 
myocardial injury results in pathological remodelling of the left ventricle 
with dilatation, impaired contractility, perfusion, fibrosis and electrical 
instability. If left untreated, these changes worsen over time, exacerbated 
by additional myocardial injury from neurohormonal imbalance resulting 
from activation of the RAAS and the sympathetic nervous system, 
increased cytokine expression, immune and inflammatory changes, altered 
fibrinolysis and oxidative stress. Reduced cardiac output results in arterial 
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underfilling, leading to renal sodium and water 
retention via activation of the above-mentioned 
neuro-endocrine systems, in an attempt to 
restore arterial circulatory integrity (Fig. 2).[7]
Clinical presentation
The history is key in making the diagnosis 
of HF, grading symptom severity, and 
establishing not only the underlying 
cause but also identifying factors that 
may have precipitated decompensation 
(Table 2). The typical symptoms of HF are 
breathlessness, orthopnoea, paroxysmal 
Heart failureHF-REF HF-PEF
The diagnosis of HF-REF
requires 3 conditions to be
satised
1.   Symptoms typical of HF
2.   Signs typical of HF
3.   Reduced LVEF <50%
The diagnosis of
HF-PEF requires 4 conditions
to be satised
1.   Symptoms typical of HF
2.   Signs typical of HF
3.   Normal (or mildly reduced)
      LVEF
4.   Relevant structural heart
      disease (LV hypertrophy/
      LA enlargement) and/or
      diastolic dysfunction    
Symptom status
Typical symptoms Specic signs
•  Breathlessness
•  Orthopnoea
•  Paroxysmal nocturnal
   dyspnoea
•  Reduced exercise
   tolerance
•  Fatigue, tiredness,
   increased time to
   recover after exercise
•  Ankle swelling
 
Less typical
symptoms
•  Nocturnal cough
•  Wheezing
•  Weight gain 
   (>2 kg/week)
•  Weight loss
   (advanced HF)
•  Bloated feeling
•  Loss of appetite
•  Confusion (elderly)
•  Depression
•  Palpitations
•  Syncope
•  Elevated jugular 
   venous pressure
•  Hepatojugular reflex
•  Third heart sound
   (gallop)
•  Laterally displaced
   apical impulse
•  Cardiac murmur
Less specic signs
•  Peripheral oedema
•  Pulmonary 
   crepitations
•  Reduced breath 
   sounds and dullness
   at lung bases (pleural
   effusion)
•  Tachycardia
•  Irregular pulse
•  Tachypnoea
•  Hepatomegaly
•  Ascites
•  Cachexia
Compensated HF
Rendered asymptomatic with treatment
NB: Although signs and symptoms may resolve,
patients' underlying cardiac dysfunction may not,
and they remain at risk for recurrent
decompensation
Decompensated HF
Worsening HF symptoms
(e.g. inadequate antifailure therapy, anaemia,
infection, non-compliance, uid intake,
new arrhythmia, acute coronary syndrome,
natural progression of disease, pregnancy,
thyrotoxicosis, myocarditis, etc.)
NB: Look for precipitant
Symptom severity: NYHA functional classication
NB: symptom severity correlates poorly with ventricular function
NYHA Class I (asymptomatic)
No limitation of physical activity. 
Ordinary physical activity does not cause
undue breathlessness, fatigue or palpitations
NYHA Class II (mild symptoms)
Slight limitation in physical activity. Comfortable at rest, but ordinary
physical activity results in undue breathlessness, fatigue, or palpitations
NYHA Class III (moderate, or moderate-severe symptoms)
Marked limitation of physical activity. Comfortable at rest, but less than
ordinary physical activity results in undue breathlessness, fatigue and
palpitations
NYHA Class IV (severe symptoms)
Unable to carry on any physical activity without discomfort. Symptoms
at rest can be present. If any physical activity is undertaken, discomfort
is increased
 
Fig. 1. Classification, clinical profile, grading of severity and natural history of heart failure (NYHA = New York Heart Association; LA = left atrial).
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nocturnal dyspnoea, reduced effort tolerance, fatigue, and ankle 
swelling. The New York Heart Association (NYHA) functional 
class allows a grading of symptom severity in a standardised 
manner (Fig. 1).[2] Exploring past medical history, environmental 
exposures and family history may assist in deciphering a possible 
aetiology. 
The physical examination findings may differ, depending on 
the underlying aetiology, but pedal oedema, raised jugular venous 
pressure, a tender hepatomegaly and basal crackles indicate congestive 
HF. Additional features that can be found on examination are listed in 
Table 3. 
Diagnostic tests in suspected HF
The baseline investigations recommended in clinical assessment 
of HF are outlined in Table 4. The electrocardiogram (ECG) and 
echocardiogram are the most useful investigations, as they confirm 
the presence of underlying structural heart disease. The likelihood of 
a normal ECG in a patient presenting with HF is low, making it an 
extremely helpful screening tool.[2] It is recommended that all patients 
with a new diagnosis of HF undergo echocardiographic evaluation as 
it confirms the type of structural heart disease present and provides 
information on cardiac function.[2] 
Understanding the aetiology of HF is vital when determining 
definitive management strategies and prognosis. The pursuit of a 
correctable cause and identification of reversible factors are central to 
improving outcomes in these patients. Patients with unexplained HF, 
particularly those who are not improving on standard therapy, should 
be referred for specialist review where advanced investigations can be 
done to establish a diagnosis (Table 4). 
Specific aetiologies of HF
Hypertension
Hypertension has been reported as the dominant cause of HF in 
Africa, responsible for up to 46% of cases of HF in hospitalised 
patients.[4,5,8] Young hypertensive patients should be investigated for 
secondary causes of hypertension (Table 1). Standard anti-failure 
therapy and blood pressure control are the mainstays of therapy.
Table 1. Diseases causing heart failure
Hypertension
Essential hypertension Unknown
Secondary 
hypertension
Primary aldosteronism (Conn syndrome), 
Cushing syndrome, phaeochromocytoma, 
chronic kidney disease, renal artery stenosis, 
coarctation of the aorta, obstructive sleep apnoea
Primary myocardial disease; cardiomyopathies and myocarditis
HCM Familial
Sporadic
Obesity, infants of diabetic mothers, amyloid, 
athletes
DCM Familial
Non-familial
Alcohol, pregnancy, tachymyopathy, 
thyrotoxicosis, myocarditis, nutritional 
(e.g. thiamine, selenium), drugs (e.g. 
anthracycline, cocaine), iron overload
ARVC Familial 
Non-familial
RCM Familial
Non-familial
Endomyocardial fibrosis, radiation, amyloid, 
carcinoid 
Unspecified 
cardiomyopathy
Familial (left ventricular non-compaction)
Non-familial (Takotsubo cardiomyopathy)
Myocarditis Infective
Viral, HIV, bacterial, fungal, helminths, 
protozoa, rickettsia, spirochetes
Toxic/hypersensitivity 
Anthracycline chemotherapy, alcohol, 
methamphetamines, other drugs
Immune
Lupus, rheumatoid arthritis, sarcoidosis
Valvular heart disease
Rheumatic heart disease, endocarditis 
(infective and non-infective), degenerative, 
myxomatous, congenital
Ischaemic heart disease
Atherosclerosis
Spasm
Atherothrombosis
Coronary artery dissection
Congenital heart disease
Atrial septal defects, ventricular septal defects, 
transposition of the great vessels, tetralogy of 
Fallot, single ventricle, patent ductus arteriosis, etc.
Continued …
Table 1. (continued) Diseases causing heart failure
Pericardial disease
Pericarditis, 
pericardial effusion, 
pericardial 
constriction
Idiopathic
Infectious 
Viral, tuberculosis, fungal
Non-infectious 
Uraemia, acute myocardial infarction, 
neoplasm, post-cardiac injury syndrome 
(trauma, cardiothoracic surgery), systemic 
auto-immune disease, mediastinal radiation
Pulmonary hypertension
Pulmonary arterial 
hypertension
Idiopathic, heritable, drugs/toxins, associated 
with connective tissue disease, HIV, 
portal hypertension, CHD, schistosomiasis, 
chronic haemolytic anaemia, viral hepatitis
Pulmonary veno-
occlusive disease
Unknown
PH due to left heart 
disease 
Rheumatic heart disease
PH due to lung 
disease and/or 
hypoxia
Post-tuberculous bronchiectasis, chronic 
obstructive pulmonary disease, occupational 
lung disease, interstitial lung disease
Chronic thrombo-
embolic PH
Thrombophilia, deep venous thrombosis
PH with unclear and/
or multifactorial 
mechanism
HCM = hypertrophic cardiomyopathy; DCM = dilated cardiomyopathy; 
ARVC = arrhythmogenic right ventricular cardiomyopathy; PH = pulmonary hypertension; 
CHD = congenital heart disease; RCM = restrictive cardiomyopathy. 
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Cardiomyopathy 
Cardiomyopathy accounts for 20 - 30% of 
heart failure in Africans.[1] Most commonly, 
patients who present with HF have a dilated 
phenotype, and potentially treatable causes for 
dilated cardiomyopathy should routinely be 
excluded (Table 1). Importantly, patients with 
other forms of cardiomyopathy (hypertrophic 
cardiomyopathy (HCM), arrhythmogenic 
right ventricular cardiomyopathy (ARVC), 
restrictive cardiomyopathy (RCM), and left 
ventricular non-compaction) presenting 
with HF should be referred for specialist 
review, as the management of these condi-
tions is complex and multi disciplinary.[9] 
Myocarditis should be considered in patients 
who present with cardiac symptoms and 
elevated cardiac biomarkers (tropo nin T or 
I), ECG abnormalities and/or evidence of 
functional impairment on echocardiogram, 
where acute coronary syndrome has been 
excluded.[10,11] Forty-four percent of HIV-
associated cardiomyopathy cases have evidence 
of myocarditis on endo myocardial biopsy, 
either as a result of HIV or secondary to 
opportunistic infections,[12] justifying anti-
retroviral therapy in these patients. 
Valvular heart disease
In contrast to Western populations, where 
valvular heart disease is mainly degenerative, 
in SSA valvular heart disease is predominantly 
caused by rheumatic fever and infective 
endocarditis. Despite a reduction in RHD 
as a cause of HF in SSA in recent years, 
it remains endemic on our continent.[13] 
The mainstay of treatment for patients with 
symptomatic valvular heart disease is surgery, 
complemented by anti-failure therapy and 
secondary prevention of rheumatic fever with 
penicillin in RHD. All patients should be 
referred for evaluation for surgery.
Ischaemic heart disease 
Ischaemic heart disease (IHD) is an uncom-
mon cause of HF in SSA, accounting for 
only 7.7 - 9% of cases.[3,4,8] Although IHD 
is considered uncommon among black 
Africans, there has been a notable rise in risk 
factors for atherosclerotic vascular disease 
in both urban and rural communities over 
the last few decades.[14] Patients presenting 
with ischaemic left ventricular dysfunction 
require rigorous risk factor management in 
addition to conventional HF therapy. Patients 
with suspected coronary artery disease with 
ongoing symptoms of angina should be 
referred to a cardiologist for consideration for 
revascularisation therapy.[2,15]
Congenital heart disease
Although the prevalence of congenital heart 
disease (CHD) in SSA is considered to be 
the lowest in the world, it is likely that this 
Injury to cardiac myocytes and
extracellular matrix
Ventricular
remodelling
Chamber dilatation, reduced contractility, brosis, reduced
compliance of the left ventricle and electrical instability
Reduction in cardiac ouput
Heart failure
Sodium and
water retention
Increased cytokine
expression, inammatory
changes, apoptosis, oxidative
stress, altered gene
expression
Extracellular matrix
remodelling leads to brosis
and activation of
collagenolytic enzymes that
lead to chamber dilatationMyocyte
hypertrophy
Reduced
arterial lling
Increased
heart rate
Neurohormonal imbalance
with activation of renin-
angiotension-aldosterone
system and sympathetic
nervous system
Fig. 2. Pathophysiology of heart failure.
Table 2. Precipitating factors to 
consider in acute decompensated heart 
failure
Anaemia
Onset of a new arrhythmia (e.g. atrial 
fibrillation/flutter, supraventricular 
tachycardia, ventricular tachycardia) 
 Hyperthyroidism
Infection
Pregnancy
Infective endocarditis
Recurrence of rheumatic fever
Renal failure
Malignant hypertension
Myocardial infarction
Non-compliance on maintenance therapy
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reflects the paucity of readily available estimates and that the true 
number of individuals affected with CHD is grossly underestimated. 
While CHD is an important cause of HF in children in SSA, it 
accounts for only a small percentage of cases of HF in adults.[16] CHD 
is riddled with complexity and requires management by experienced 
clinicians.[2]
Pericardial disease 
Pericardial disease has a broad aetiology, but tuberculous pericarditis 
is the commonest cause of pericardial effusion, cardiac tampo nade, 
and constrictive pericarditis in SSA, and carries a high mortality 
rate despite antituberculosis therapy, pericardiocentesis and peri-
cardectomy.[17] 
Pulmonary hypertension 
PH is a debilitating progressive disease that leads to right HF, and 
although little is currently known about the epidemiology of PH 
in Africa, the reported incidence appears to be higher than in 
developed countries. The Pan African Pulmonary Hypertension 
Cohort study hopes to address the paucity of our knowledge. 
Importantly, many risk factors associated with PH are endemic 
in SSA (Table 1).[18] PH (not associated with left heart pathology) 
requires investigation in the absence of significant pulmonary 
disease. 
Management of HF
Although a significant portion of HF management falls within 
the realm of the general practitioner and general physician, it is 
important to be able to recognise which patients require specialist 
referral, particularly where there is diagnostic uncertainty and/or 
failure to improve, or deterioration, on anti-failure therapy.
The goals of treatment in patients with established HF are to: (i) relieve 
symptoms with the aim to improve quality of life and functional capacity; 
(ii) prevent recur rent hospitalisations; and (iii) improve survival. In SSA 
these goals are achieved predominantly through patient education 
and medical therapy. Despite resource restraints, there is a role 
for advanced medical, device and surgical interventions, including 
orthotopic heart transplantation, for HF in SSA. It is important for 
Table 3. Additional examination findings in heart failure
Structural heart disease/
aetiology
Examination findings that could 
be present
Conditions that result in left 
ventricular dilatation and 
systolic dysfunction
Laterally displaced apex, a third 
heart sound, cardiac murmur
Pulmonary hypertension Palpable and/or loud pulmonary 
component of the second 
heart sound, parasternal heave, 
pulmonary pathology, cyanosis, 
clubbing
Pericardial disease Elevated venous pressure, 
pedal oedema and ascites, 
unremarkable precordial 
examination and clear lung fields
Pericardial rub may be present in 
pericarditis
Hypotension, distended neck 
veins, muffled heart sounds, and 
pulsus paradoxus are suggestive 
of pericardial effusion with 
tamponade
Diastolic knock may be present in 
constrictive pericarditis
Congenital heart disease Depending on underlying cardiac 
lesion; cardiac murmur, signs 
of pulmonary hypertension, 
parasternal heave (right ventri-
cular hypertrophy), fixed split of 
the second heart sound (atrial 
septal defect), cyanosis, clubbing, 
surgical scars
Radial-radial delay, radial-
femoral delay may be present in 
coarctation of the aorta
Hypertensive heart disease Blood pressure may be elevated, 
or normal in end-stage disease 
Pressure-loaded apex beat, loud 
aortic component of the second 
heart sound, fourth heart sound 
Evidence of target organ damage 
(retinopathy, proteinuria) 
Table 4. Investigations in heart failure
Baseline investigations
Pro-BNP/BNP Elevated in heart failure
Not routinely required
Electrocardiogram Heart rate and rhythm disturbances 
(atrial fibrillation/flutter)
Electrical conduction abnormalities 
(left or right bundle branch block, 
heart block)
Cardiac wall and/or chamber abnormalities 
(ventricular hypertrophy, atrial enlargement, 
Q-waves)
Chest radiograph Cardiac size and shape (cardiomegaly)
Pulmonary congestion
Presence or absence of pulmonary pathology
Echocardiogram Chamber size
Systolic and diastolic function
Ventricular wall thickness
Valve morphology and function
Advanced investigations
Cardiovascular 
magnetic resonance 
imaging
Cardiac structure, size and function
Tissue characterisation
Perfusion imaging
Late gadolinium imaging (scar)
Velocity-encoded flow imaging
Defining anatomy in complex CHD
Cardiac computed 
tomography
Coronary artery angiography
Nuclear medicine 
imaging
Cardiac function (right and left ventricular 
ejection fraction)
Myocardial perfusion studies
Angiography Haemodynamic assessment 
Coronary artery angiography
Endomyocardial 
biopsy
Histological diagnosis
BNP = brain natriuretic peptide; CHD = congenital heart disease.
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clinicians to familiarise themselves with the 
indica tions and the availability of services.[2] 
Patient education 
It is the attending clinicians’ responsibility 
to inform patients about their condition. 
Important aspects to consider are listed in 
Table 5. 
Optimising medical 
therapy
Medical therapy consists of two components: 
(i) disease-modifying drugs consisting of three 
neurohormonal antagonists (angiotensin-
converting enzyme (ACE) inhibitors (or 
angiotensin receptor blockers), beta-blockers, 
and mineralocorticoid receptor antagonists) 
that are fundamental in modifying the 
course of disease and improving survival; 
and (ii) symptomatic therapies, such as 
diuretics and digoxin, that relieve congestion, 
reduce hospitalisation and improve quality 
of life. 
Fig. 3 illustrates an approach for the medi-
cal management of HF. The first step is to 
manage and alleviate congestion. Disease-
modifying drugs should be introduced at 
recommended starting doses and titrated 
up to maximum tolerated doses over a 
number of weeks (Table 6).[2] Digoxin has 
been shown to relieve symptoms and reduce 
hospitalisations,[19] but is associated with an 
increase in mortality in HF patients.[20] Current 
guidelines recommend low-dose digoxin in 
selected patients who remain symptomatic 
despite optimal ACE inhibitor and beta-
blocker therapy. Hypokalaemia and renal 
failure predispose patients to digoxin toxicity, 
and its use is contraindicated in these 
circumstances.[21]  
The prognosis of acute decompensated 
HF remains poor, with greater severity of 
congestion being associated with worse 
outcomes. Acute decompensated HF is asso-
ciated with an in-hospital mortality rate of 
up to 8.3% in Africa.[8] Fluid retention and 
congestion are responsible for 90% of HF 
hospital admissions, and even with diuretic 
therapy approximately 40% of patients are 
discharged with unresolved congestion.[22] 
The mainstay therapy for the treatment 
of congestion is loop diuretics. Diuretic 
resistance is the failure to adequately control 
salt and water retention despite appropriate 
dose escalation of loop diuretics. The dose-
response curve for loop diuretics shifts 
in HF, resulting in the need for increased 
doses of the drug to achieve a therapeutic 
effect; thus inadequate dosing must be 
differentiated from diuretic resistance. 
Infrequent dosing can result in rebound 
salt and water retention, which can be 
addressed by increasing the frequency 
of dosing or changing to a continuous 
intravenous infusion. 
Strategies for overcoming diuretic resis-
tance include the addition of thiazide diuretics 
and/or spironolactone. Importantly, diuretic 
combinations can result in severe volume 
depletion and electrolyte disturbances, and 
should only be used in circumstances 
where volume status and electrolytes can 
be monitored. RAAS activation plays an 
important role in sodium and water retention 
by increasing distal sodium reabsorption 
in the kidney. Introducing ACE inhibitors 
is crucial in managing congestion. The 
challenge is maintaining adequate arterial 
blood pressure, as low blood pressure drives 
plasma renin activity and further activation 
of RAAS (Fig. 4).[22]
Advanced medical, 
device and surgical 
interventions
Heart rate reduction improves clinical out comes 
in HF. Beta-blocker dosage should be titrated to 
maintain a resting heart rate <75 beats/minute. 
In instances where patients are unable to tolerate 
increased doses of beta-blockers, ivabradine can 
be considered. Ivabradine inhi bits the If channel 
in the sinus node and can be used to slow the 
heart rate in patients in sinus rhythm.[2]
Indications for device and surgical 
interventions are listed in Table 7.[2,23]
Conclusion 
HF is a common condition that is caused by 
a diverse group of aetiologies, representing 
unique disease entities that require different 
management strategies. It is for this reason 
Table 5. Patient education
Patients should be well informed about:
What heart failure is and why symptoms occur
The underlying cause of their heart failure 
Prognosis
The treatment options available to them
Patients must be educated about:
 Medications, specifically the role of each drug used to treat heart failure
 Fluid retention and how to manage it (i.e. how to restrict fluids, monitor weight and 
adjust diuretic therapy accordingly)
 Remembering the names, doses and frequency of medication they are on or bringing the 
drugs to hospital with them
Patients should be encouraged to make realistic decisions regarding:
 Their ability to work. Temporary or permanent disability grant applications should be made 
if anticipated time away from work is ≥6 months 
 Financial implications related to loss of employment or added healthcare costs 
Legal issues in the event of their death
Obtaining medical aid, where possible
Patients are at increased risk of depression and may require referral for counselling or 
antidepressant drug therapy
Exercise 
An active lifestyle should be encouraged 
 Heart rate monitoring can be helpful in guiding patients with regard to safe levels of exercise 
 Aiming for a maximum heart rate of (180 – age – 20) beats/minute during exercise is 
recommended
Excessive alcohol consumption should be discouraged and excessive use of caffeine/stimulants 
avoided 
The dangers of illicit drug use should be addressed   
In women, pregnancy and contraception should be discussed: 
Contraception is recommended in all patients with cardiac disease
 Women need to be well informed of the dangers of pregnancy, particularly in the setting of 
LVEF <45%, pulmonary hypertension or mitral stenosis 
 Patients should be informed that medication used to treat heart failure, such as ACE 
inhibitors, are teratogenic 
 Patients who strongly desire a pregnancy, or who have fallen pregnant inadvertently, should 
be referred to a specialist centre for assessment 
 Pregnant patients with underlying cardiac disease are at extremely high risk and require a 
multidisciplinary team (cardiologist, obstetrician, anaesthetist) to manage them throughout 
their pregnancy, during delivery and post partum 
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Persistent symptoms of heart failure
NYHA Class II - IV
Symptoms and signs of congestion No symptoms and signs of congestion
Diuresis (Fig. 4)
Loop diuretics
+
If renal function is normal, add
mineralocorticoid receptor antagonist
In cases of diuretic resistance, add thiazide
diuretic
Monitor uid status and electrolytes
Add low-dose ACE inhibitors (or ARB)
Slowly titrate to maximum tolerated dose
Once congestion has resolved, introduce
beta-blockers at low dose
Slowly titrate to maximum tolerated dose
Introduce disease-modifying drugs (Table 6)
ACE inhibitors (or ARB) and beta-blockers
can be introduced one at a time, or
simultaneously, at low doses. Titrate to
maximum tolerated doses over a number of
weeks
+
Mineralocorticoid receptor antagonist
Monitor renal function and potassium
Consider the following:
•  Has the underlying aetiology of the heart been adequately addressed?
•  Is the patient still congested? Ask about uid intake
•  Is the patient compliant on medication? Ask about side-eects
•  Is the patient on optimal (tolerated) doses of ACE inhibitors, beta-blockers and mineralocorticoid antagonists?
•  Are there any exacerbating factors or an alternative pathology causing these symptoms? (Table 2)
   e.g. anaemia, new arrhythmia, ischaemia, infection, thyroid disease, pregnancy, renal impairment, autoimmune
   conditions, lung disease, depression, diabetes
•  Consider low-dose digoxin if renal function is normal
ASSESSMENT BY CARDIOLOGIST
CONSIDERATION FOR DEVICE AND/OR SURGICAL INTERVENTION, INCLUDING TRANSPLANTATION (Table 7)
Sinus rhythm and heart rate ≥75 beats/minute → consider ivabradine
Refractory heart failure, QRS duration >120 ms and LVEF ≤35% → consider cardiac resynchronisation therapy
Fig. 3. Approach to management of heart failure (ARB = angiotensin receptor blocker).
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that diagnostic certainty is as important 
as treating the clinical syndrome of HF. 
Effective diuresis and complete resolution 
of congestion is key in improving symptoms 
and functional capacity, reducing the need 
for recurrent hospitalisation, increasing 
the probability of establishing patients on 
good doses of disease-modifying drugs, and 
ultimately improving outcomes. 
Table 6. Disease-modifying drugs used in heart failure[2]
Drugs Starting dose Target dose Recommendation
Level of 
evidence
ACE inhibitors
Captopril
Enalapril
Lisinopril
Perindopril
Ramipril
Trandolapril
6.25 mg 3 × /day
2.5 mg 2 × /day
2.5 - 5.0 mg daily
2.0 mg daily
2.5 mg daily
0.5 mg daily
50 mg 3 × /day
10 - 20 mg 2 × /day
20 - 35 mg daily
4.0 mg daily
5.0 mg 2 × /day
4.0 mg daily
Recommended, in addition to beta-blockers, for all patients with 
LVEF ≤40% to reduce risk of HF hospitalisation and premature death
IA
Beta-blockers
Bisoprolol
Carvedilol
 Metoprolol 
succinate
1.25 mg daily
3.125 mg 2 × /day
12.5 - 25 mg daily
10 mg daily
25 - 50 mg 2 × /day
200 mg daily
Recommended, in addition to ACE inhibitors, for all patients with 
LVEF ≤40% to reduce risk of HF hospitalisation and premature death
IA
Angiotensin II receptor blockers 
Candesartan
Valsartan
Losartan
Telmisartan
4 mg or 8 mg daily
40 mg 2 × /day
50 mg daily
20 mg daily
32 mg daily
160 mg 2 × /day
150 mg daily
80 mg daily
Recommended as an alternative to ACE inhibitors, in patients with 
LVEF ≤40% to reduce risk of HF, hospitalisation and premature death
IA
Mineralocorticoid receptor antagonists 
Spirono-
lactone
Eplerenone
25 mg daily
25 mg daily
25 - 50 mg daily
50 mg daily
Recommended for all patients with persisting symptoms and an 
LVEF ≤35% despite treatment with an ACE inhibitor and a beta-
blocker to reduce risk of HF hospitalisation and premature death
IA
Mineralocorticoid receptor
antagonists
ACE inhibitors
Thiazide diuretics
Loop diuretics
Inhibition of the
Na /CI-/K
co-transporter, resulting
in reduced sodium and
 chloride reabsorption
proximally (kidney)
++
Prostaglandin
synthesis
Vascular smooth
muscle relaxation and
vasodilatation
Natriuresis
and diuresis
Increased sodium
delivery distally
(kidney)
Heart failure
Reduced cardiac
output
Activation of
RAAS
Secondary
hyperaldosteronism
Increased absorption of
sodium distally (kidney)
Sodium and water
retention
Fig. 4. Mechanisms of action of pharmacotherapy used in heart failure management.
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Table 7. Device and surgical interventions in heart failure[2,23]
Intervention Indication
ICD Secondary prevention
 Survivors of cardiac arrest or patients with sustained symptomatic ventricular tachycardia, irrespective of LVEF
Good functional status
Expected survival >1 year
Primary prevention (limited availability in SSA)
LVEF ≤35%
Symptomatic (NYHA Class II - III) despite ≥3 months on optimal medical therapy
Increased risk of SCD in conditions such as ARVC and HCM
CRT Cardiac resynchronisation therapy should be considered in patients who fulfil the following criteria 
Typical LBBB (QRS ≥120 ms)
Persistent symptoms despite ≥3 months of optimal medical therapy 
NYHA Class III/IV (ambulatory) 
LVEF ≤35% and an expected survival >1 year
Right bundle branch block and prolonged PR interval are predictors of non-favourable outcomes
Mechanical circulatory support Limited availability in SSA
Drug-refractory acute circulatory collapse and at immediate risk of death
To sustain life, as a bridge to decision/candidacy for transplantation or as a bridge to transplantation, recovery or 
destination therapy
Heart transplantation End-stage heart failure with severe symptoms, a poor prognosis, and no remaining alternative treatment option
Motivated, well-informed, and emotionally stable 
Capable of complying with the intense treatment required postoperatively
Contraindications to transplantation
 Active infection, significant comorbidities (e.g. severe peripheral vascular disease, cerebrovascular disease, 
renal failure, liver disease, systemic multiorgan disease), recurrent thromboembolism, unhealed peptic ulcer, 
current alcohol or drug abuse, emotional/psychiatric instability, cancer within the previous 5 years
High, fixed pulmonary vascular resistance (>4 - 5 Wood units and mean transpulmonary gradient >5 mmHg)
ICD = implantable cardioverter-defibrillator; CRT = cardiac resynchronisation therapy; SCD = sudden cardiac death; HCM = hypertrophic cardiomyopathy. 
